Premium
Moclobemide compared with second‐generation antidepressants in elderly people
Author(s) -
Vanna M. De,
Kummer J.,
Agnoli A.,
Gentili P.,
Lorizio A.,
Anand R.
Publication year - 1990
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1990.tb05335.x
Subject(s) - moclobemide , maprotiline , mianserin , medicine , randomized controlled trial , major depressive episode , depression (economics) , psychology , antidepressant , macroeconomics , hydrocortisone , hippocampus , economics
Two multicentre studies are described here; the first compared moclobemide with mianserin and the second with maprotiline, both in elderly patients with a DSM‐III diagnosis of major depressive episode. In the first study, 80 eligible patients were randomized to either moclobemide 300–500 mg or mianserin 75–125 mg per day for 4 weeks. Mean reduction in Hamilton Rating Scale for Depression (HRSD) score was 52% in both groups. The overall assessment of efficacy was good or very good for 60% of the patients, and tolerance was considered good or very good for 85% of the patients in both groups; no significant differences between the 2 treatments were seen. The second study comprised 39 hospitalized patients randomized to either moclobemide 150–300 mg daily or maprotiline 75–150 mg daily for 6 weeks. At the end of treatment, HRSD scores declined 85% in both groups compared with baseline. The overall assessment of efficacy was over 90% good or very good in both groups. Tolerance was rated good or very good for 80% of moclobemide and 75% of maprotiline patients; none of these results differed significantly between the groups, indicating that moclobemide is as effective in elderly patients as the 2 second‐generation antidepressants. In view of the safety of moclobemide, it should be considered first‐line therapy for depression in elderly people.